LRRK2 Inhibitors as Promising Treatment for Parkinson's Disease
Shuoyan Tan1,2, Huanxiang Liu3, Xiaojun Yao3
1College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Abstract:
Parkinson's disease (PD) is one of the most prevalent neurodegenerative disorders, with current treatments offering only temporary symptomatic relief. There is an urgent need for the development of novel therapeutic approaches. Abnormal increases in LRRK2 kinase activity have been identified in both sporadic and familial PD patients, suggesting that inhibiting LRRK2 kinase activity presents a promising avenue for the pursuit of effective PD treatment strategies. In this Viewpoint, we discuss the exciting new insights regarding the development of LRRK2 kinase inhibitors as a treatment for Parkinson's disease.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Neural Regulation
Lysosomal Hydrolases
EPS and iPS Cells in Disease Research
Targeted Cancer Therapies
There are several types of targeted therapies against...


